Therefore, combination immunotherapy against CEACAM6, to enhance the body’s immune system, and other non-5-FU-based chemotherapy regimens should be considered for the treatment of early- and advanced-stage GC. This evidence concerns the gene CEACAM6 and gastric cancer.